These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Krarup-Hansen A; Fugleholm K; Helweg-Larsen S; Hauge EN; Schmalbruch H; Trojaborg W; Krarup C Brain; 1993 Oct; 116 ( Pt 5)():1017-41. PubMed ID: 8221046 [TBL] [Abstract][Full Text] [Related]
4. Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Ashraf M; Riggs JE; Wearden S; Scotchel P Gynecol Oncol; 1990 Apr; 37(1):29-33. PubMed ID: 2157640 [TBL] [Abstract][Full Text] [Related]
5. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Krarup-Hansen A; Helweg-Larsen S; Schmalbruch H; Rørth M; Krarup C Brain; 2007 Apr; 130(Pt 4):1076-88. PubMed ID: 17301082 [TBL] [Abstract][Full Text] [Related]
6. Sensory action potentials and biopsy of the sural nerve in neuropathy. Behse F; Buchthal Brain; 1978 Sep; 101(3):473-93. PubMed ID: 213163 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. Fu KK; Kai EF; Leung CK J Clin Pharm Ther; 1995 Jun; 20(3):167-72. PubMed ID: 7593379 [TBL] [Abstract][Full Text] [Related]
8. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. Boogerd W; ten Bokkel Huinink WW; Dalesio O; Hoppenbrouwers WJ; van der Sande JJ J Neurooncol; 1990 Dec; 9(3):255-63. PubMed ID: 2128320 [TBL] [Abstract][Full Text] [Related]
9. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cavaletti G; Bogliun G; Marzorati L; Zincone A; Marzola M; Colombo N; Tredici G Cancer; 1995 Mar; 75(5):1141-50. PubMed ID: 7850713 [TBL] [Abstract][Full Text] [Related]
10. Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment. Pirovano C; Balzarini A; Böhm S; Oriana S; Spatti GB; Zunino F Tumori; 1992 Aug; 78(4):253-7. PubMed ID: 1334604 [TBL] [Abstract][Full Text] [Related]
11. rhGGF2 protects against cisplatin-induced neuropathy in the rat. ter Laak MP; Hamers FP; Kirk CJ; Gispen WH J Neurosci Res; 2000 Apr; 60(2):237-44. PubMed ID: 10740229 [TBL] [Abstract][Full Text] [Related]
12. Peripheral neuropathy after cis-platinum (II) (DDP) therapy. Reinstein L; Ostrow SS; Wiernik PH Arch Phys Med Rehabil; 1980 Jun; 61(6):280-2. PubMed ID: 6246848 [TBL] [Abstract][Full Text] [Related]
13. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. Hansen SW; Helweg-Larsen S; Trojaborg W J Clin Oncol; 1989 Oct; 7(10):1457-61. PubMed ID: 2476531 [TBL] [Abstract][Full Text] [Related]
14. Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer. Sebille A; St-Guily JL; Angelard B; de Stabenrath A Cancer; 1990 Jun; 65(12):2644-7. PubMed ID: 2160314 [TBL] [Abstract][Full Text] [Related]
15. [Subclinical lesions of peripheral nervous system in multiple sclerosis patients]. Pogorzelski R; Baniukiewicz E; Drozdowski W Neurol Neurochir Pol; 2004; 38(4):257-64. PubMed ID: 15383952 [TBL] [Abstract][Full Text] [Related]